In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity

Infection and Immunity

Volumn 75, Issue 11, 2007, Pages 5443-5452

  Staats, Herman F ^a   Alam, S Munir ^a   Scearce, Richard M ^a   Kirwan, Shaun M ^a   Zhang, Julia Xianzhi ^a   Gwinn, William M ^a   Haynes, Barton F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX LETHAL FACTOR; ANTHRAX PROTECTIVE ANTIGEN; ANTHRAX TOXIN; LETHAL FACTOR ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 27H11; MONOCLONAL ANTIBODY 3F11; MONOCLONAL ANTIBODY 9A11; NEUTRALIZING ANTIBODY; PROTECTIVE ANTIGEN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBODY PRODUCTION; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL VIRULENCE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNOPROPHYLAXIS; LD 50; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL;

ANIMALS; ANTHRAX; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIGENS, BACTERIAL; ANTITOXINS; BACILLUS ANTHRACIS; BACTERIAL TOXINS; CELL LINE; CELL SURVIVAL; FEMALE; IMMUNIZATION, PASSIVE; MACROPHAGES; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS;

EID: 35648942194     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.00529-07     Document Type: Article

References (60)

1. Alam, S. M., M. McAdams, D. Boren, M. Rak, R. M. Scearce, F. Gao, Z. T. Camacho, D. Gewirth, G. Kelsoe, P. Chen, and B. F. Haynes. 2007. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J. Immunol. 178:4424-4435.
2. Alam, S. M., C. A. Paleos, H. X. Liao, R. Scearce, J. Robinson, and B. F. Haynes. 2004. An inducible HIV type 1 gp41 HR-2 peptide-binding site on HIV type 1 envelope gp120. AIDS Res. Hum. Retrovir. 20:836-845.
3. Beedham, R. J., P. C. Turnbull, and E. D. Williamson. 2001. Passive transfer of protection against Bacillus anthracis infection in a murine model. Vaccine 19:4409-4416.
4. Besselaar, T. G., and N. K. Blackburn. 1992. The synergistic neutralization of Rift Valley fever virus by monoclonal antibodies to the envelope glycoproteins. Arch. Virol. 125:239-250.
5. Bhatnagar, R., and S. Batra. 2001. Anthrax toxin. Crit. Rev. Microbiol. 27:167-200.
6. Borio, L., D. Frank, V. Mani, C. Chiriboga, M. Pollanen, M. Ripple, S. Ali, C. DiAngelo, J. Lee, J. Arden, J. Titus, D. Fowler, T. O'Toole, H. Masur, J. Bartlett, and T. Inglesby. 2001. Death due to bioterrorism-related inhalational anthrax: report of 2 patients. JAMA 286:2554-2559.
7. Boyaka, P. N., A. Tafaro, R. Fischer, S. H. Leppla, K. Fujihashi, and J. R. McGhee. 2003. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J. Immunol. 170:5636-5643.
8. Bradney, C. P., G. D. Sempowski, H. X. Liao, B. F. Haynes, and H. F. Staats. 2002. Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization. J. Virol. 76:517-524.
9. Brossier, F., M. Levy, A. Landier, P. Lafaye, and M. Mock. 2004. Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies. Infect. Immun. 72:6313-6317.
10. Cui, X., Y. Li, M. Moayeri, G. H. Choi, G. M. Subramanian, X. Li, M. Haley, Y. Fitz, J. Feng, S. M. Banks, S. H. Leppla, and P. Q. Eichacker. 2005. Late treatment with a protective antigen-directed monoclonal antibody improves hemodynamic function and survival in a lethal toxin-infused rat model of anthrax sepsis. J. Infect. Dis. 191:422-434.
11. Cui, X., M. Moayeri, Y. Li, X. Li, M. Haley, Y. Fitz, R. Correa-Araujo, S. M. Banks, S. H. Leppla, and P. Q. Eichacker. 2004. Lethality during continuous anthrax lethal toxin infusion is associated with circulatory shock but not inflammatory cytokine or nitric oxide release in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 286:R699-R709.
12. Dewan, P. K., A. M. Fry, K. Laserson, B. C. Tierney, C. P. Quinn, J. A. Hayslett, L. N. Broyles, A. Shane, K. L. Winthrop, I. Walks, L. Siegel, T. Hales, V. A. Semenova, S. Romero-Steiner, C. Elie, R. Khabbaz, A. S. Khan, R. A. Hajjeh, A. Schuchat, D. C. A. R. T. Washington, P. M. Dull, K. E. Wilson, B. Kournikakis, E. A. Whitney, C. A. Boulet, J. Y. Ho, J. Ogston, M. R. Spence, M. M. McKenzie, M. A. Phelan, T. Popovic, and D. Ashford. 2002. Inhalational anthrax outbreak among postal workers, Washington, D.C., 2001. Emerg. Infect. Dis. 8:1066-1072.
13. Dull, P. M., K. E. Wilson, B. Kournikakis, E. A. Whitney, C. A. Boulet, J. Y. Ho, J. Ogston, M. R. Spence, M. M. McKenzie, M. A. Phelan, T. Popovic, and D. Ashford. 2002. Bacillus anthracis aerosolization associated with a contaminated mail sorting machine. Emerg. Infect. Dis. 8:1044-1047.
14. Eisenbarth, G. S., H. Oie, A. Gazdar, W. Chick, J. A. Schultz, and R. M. Scearce. 1981. Production of monoclonal antibodies reacting with rat islet cell membrane antigens. Diabetes 30:226-230.
15. Fellows, P. F., M. K. Linscott, B. E. Ivins, M. L. Pitt, C. A. Rossi, P. H. Gibbs, and A. M. Friedlander. 2001. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 19:3241-3247.
16. Greene, C. M., J. Reefhuis, C. Tan, A. E. Fiore, S. Goldstein, M. J. Beach, S. C. Redd, D. Valiante, G. Burr, J. Buehler, R. W. Pinner, E. Bresnitz, B. P. Bell, et al. 2002. Epidemiologic investigations of bioterrorism-related anthrax, New Jersey, 2001. Emerg. Infect. Dis. 8:1048-1055.
17. Hall, E. R., T. F. Wierzba, C. Ahren, M. R. Rao, S. Bassily, W. Francis, F. Y. Girgis, M. Safwat, Y. J. Lee, A.-M. Svennerholm, J. D. Clemens, and S. J. Savarino. 2001. Induction of systemic antifimbria and antitoxin antibody responses in Egyptian children and adults by an oral, killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine Infect. Immun. 69:2853-2857.
18. Hull, A. K., C. J. Criscuolo, V. Mett, H. Groen, W. Steeman, H. Westra, G. Chapman, B. Legutki, L. Baillie, and V. Yusibov. 2005. Human-derived, plant-produced monoclonal antibody for the treatment of anthrax. Vaccine 23:2082-2086.
19. Ivins, B. E., M. L. Pitt, P. F. Fellows, J. W. Farchaus, G. E. Benner, D. M. Waag, S. F. Little, G. W. Anderson, Jr., P. H. Gibbs, and A. M. Friedlander. 1998. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 16:1141-1148.
20. Ivins, B. E., S. L. Welkos, S. F. Little, M. H. Crumrine, and G. O. Nelson. 1992. Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants. Infect. Immun. 60:662-668.
21. Jiang, G., S. B. Joshi, L. J. Peek, D. T. Brandau, J. Huang, M. S. Ferriter, W. D. Woodley, B. M. Ford, K. D. Mar, J. A. Mikszta, C. R. Hwang, R. Ulrich, N. G. Harvey, C. R. Middaugh, and V. J. Sullivan. 2006. Anthrax vaccine powder formulations for nasal mucosal delivery. J. Pharm. Sci. 95:80-96.
22. Katial, R. K., B. L. Brandt, E. E. Moran, S. Marks, V. Agnello, and W. D. Zollinger. 2002. Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine. Infect. Immun. 70:702-707.
23. Kobiler, D., Y. Gozes, H. Rosenberg, D. Marcus, S. Reuveny, and Z. Altboum. 2002. Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization. Infect. Immun. 70:544-560.
24. Lane, H. C., and A. S. Fauci. 2001. Bioterrorism on the home front: a new challenge for American medicine. JAMA 286:2595-2597.
25. Li, A., T. W. Baba, J. Sodroski, S. Zolla-Pazner, M. K. Gorny, J. Robinson, M. R. Posner, H. Katinger, C. F. Barbas III, D. R. Burton, T. C. Chou, and R. M. Ruprecht. 1997. Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins. AIDS Res. Hum. Retrovir. 13:647-656.
26. Lim, N.-K., J.-H. Kim, M. S. Oh, S. Lee, S.-Y. Kim, K.-S. Kim, H.-J. Kang, H. J. Hong, and K.-S. Inn. 2005. An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin. Infect. Immun. 73:6547-6551.
27. Little, S. F., B. E. Ivins, P. F. Fellows, and A. M. Friedlander. 1997. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect. Immun. 65:5171-5175.
28. Little, S. F., B. E. Ivins, P. F. Fellows, M. L. M. Pitt, S. L. W. Norris, and G. P. Andrews. 2004. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 22:422-430.
29. Little, S. F., S. H. Leppla, and E. Cora. 1988. Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect. Immun. 56:1807-1813.
30. Little, S. F., S. H. Leppla, and A. M. Friedlander. 1990. Production and characterization of monoclonal antibodies against the lethal factor component of Bacillus anthracis lethal toxin. Infect. Immun. 58:1606-1613.
31. Lobach, D. F., R. M. Scearce, and B. F. Haynes. 1985. The human thymic microenvironment. Phenotypic characterization of Hassall's bodies with the use of monoclonal antibodies. J. Immunol. 134:250-257.
32. Mabry, R., M. Rani, R. Geiger, G. B. Hubbard, R. Carrion, Jr., K. Brasky, J. L. Patterson, G. Georgiou, and B. L. Iverson. 2005. Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc region. Infect. Immun. 73:8362-8368.
33. Mayer, T. A., S. Bersoff-Matcha, C. Murphy, J. Earls, S. Harper, D. Pauze, M. Nguyen, J. Rosenthal, D. Cerva, Jr., G. Druckenbrod, D. Hanfling, N. Fatteh, A. Nayyar, and E. L. Berman. 2001. Clinical presentation of inhalational anthrax following bioterrorism exposure: report of 2 surviving patients. JAMA 286:2549-2553.
34. Maynard, J. A., C. B. Maassen, S. H. Leppla, K. Brasky, J. L. Patterson, B. L. Iverson, and G. Georgiou. 2002. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat. Biotechnol. 20:597-601.
35. McFarland, E. J., R. M. Scearce, and B. F. Haynes. 1984. The human thymic microenvironment: cortical thymic epithelium is an antigenically distinct region of the thymic microenvironment. J. Immunol. 133:1241- 1249.
36. Mikszta, J. A., V. J. Sullivan, C. Dean, A. M. Waterston, J. B. Alarcon, J. P. Dekker III, J. M. Brittingham, J. Huang, C. R. Hwang, M. Ferriter, G. Jiang, K. Mar, K. U. Saikh, B. G. Stiles, C. J. Roy, R. G. Ulrich, and N. G. Harvey. 2005. Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms. J. Infect. Dis. 191:278-288.
37. Moayeri, M., D. Haines, H. A. Young, and S. H. Leppla. 2003. Bacillus anthracis lethal toxin induces TNF-α-independent hypoxia-mediated toxicity in mice. J. Clin. Investig. 112:670-682.
38. Mohamed, N., M. Clagett, J. Li, S. Jones, S. Pincus, G. D'Alia, L. Nardone, M. Babin, G. Spitalny, and L. Casey. 2005. A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect. Immun. 73:795-802.
39. Mohamed, N., J. Li, C. S. Ferreira, S. F. Little, A. M. Friedlander, G. L. Spitalny, and L. S. Casey. 2004. Enhancement of anthrax lethal toxin cytotoxicity: a subset of monoclonal antibodies against protective antigen increases lethal toxin-mediated killing of murine macrophages. Infect. Immun. 72:3276-3283.
40. NIAID. 2007. NIAID category A, B & C priority pathogens. NIAID, NIH, Bethesda, MD.
41. Nordone, S. K., J. W. Peacock, S. M. Kirwan, and H. F. Staats. 2006. Capric acid and hydroxypropylmethylcellulose increase the immunogenicity of nasally administered peptide vaccines. AIDS Res. Hum. Retrovir. 22:558-568.
42. Nowakowski, A., C. Wang, D. B. Powers, P. Amersdorfer, T. J. Smith, V. A. Montgomery, R. Sheridan, R. Blake, L. A. Smith, and J. D. Marks. 2002. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc. Natl. Acad. Sci. USA 99:11346-11350.
43. Olive, C., M. Batzloff, A. Horvath, T. Clair, P. Yarwood, I. Toth, and M. F. Good. 2003. Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens. Infect. Immun. 71:2373-2383.
44. Palker, T. J., R. M. Scearce, W. Ho, T. D. Copeland, S. Oroszlan, M. Popovic, and B. F. Haynes. 1985. Monoclonal antibodies reactive with human T cell lymphotropic virus I (HTLVI) p19 internal core protein: cross-reactivity with normal tissues and differential reactivity with HTLV types I and II. J. Immunol. 135:247-254.
45. Palker, T. J., R. M. Scearce, S. E. Miller, M. Popovic, D. P. Bolognesi, R. C. Gallo, and B. F. Haynes. 1984. Monoclonal antibodies against human T cell leukemia-lymphoma virus (HTLV) p24 internal core protein. Use as diagnostic probes and cellular localization of HTLV. J. Exp. Med. 159:1117-1131.
46. Peachman, K. K., M. Rao, C. R. Alving, R. Burge, S. H. Leppla, V. B. Rao, and G. R. Matyas. 2006. Correlation between lethal toxin-neutralizing antibody liters and protection from intranasal challenge with Bacillus anthracis Ames strain spores in mice after transcutaneous immunization with recombinant anthrax protective antigen. Infect. Immun. 74:794-797.
47. Pitt, M. L., S. F. Little, B. E. Ivins, P. Fellows, J. Barth, J. Hewetson, P. Gibbs, M. Dertzbaugh, and A. M. Friedlander. 2001. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 19:4768-4773.
48. Pittman, P. R., S. F. Leitman, J. G. B. Oro, S. L. Norris, N. M. Marano, M. V. Ranadive, B. S. Sink, and K. T. McKee, Jr. 2005. Protective antigen and toxin neutralization antibody patterns in anthrax vaccinees undergoing serial plasmapheresis. Clin. Diagn. Lab. Immunol. 12:713-721.
49. Pittman, P. R., J. A. Mangiafico, C. A. Rossi, T. L. Cannon, P. H. Gibbs, G. W. Parker, and A. M. Friedlander. 2001. Anthrax vaccine: increasing intervals between the first two doses enhances antibody response in humans. Vaccine 19:213-216.
50. Price, B. M., A. L. Liner, S. Park, S. H. Leppla, A. Mateczun, and D. R. Galloway. 2001. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect. Immun. 69:4509-4515.
51. Reuveny, S., M. D. White, Y. Y. Adar, Y. Kafri, Z. Altboum, Y. Gozes, D. Kobiler, A. Shafferman, and B. Velan. 2001. Search for correlates of protective immunity conferred by anthrax vaccine. Infect. Immun. 69:2888-2893.
52. Scearce, R. M., and G. S. Eisenbarth. 1983. Production of monoclonal antibodies reacting with the cytoplasm and surface of differentiated cells. Methods Enzymol. 103:459-469.
53. Sloat, B. R., and Z. Cui. 2006. Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli. Vaccine 24:6405-6413.
54. Tan, C. G., H. S. Sandhu, D. C. Crawford, S. C. Redd, M. J. Beach, J. W. Buehler, E. A. Bresnitz, R. W. Pinner, B. P. Bell, et al. 2002. Surveillance for anthrax cases associated with contaminated letters, New Jersey, Delaware, and Pennsylvania, 2001. Emerg. Infect. Dis. 8:1073-1077.
55. Telen, M. J., R. M. Scearce, and B. F. Haynes. 1987. Human erythrocyte antigens. III. Characterization of a panel of murine monoclonal antibodies that react with human erythrocyte and erythroid precursor membranes. Vox Sanguinis 52:236-243.
56. Wild, M. A., H. Xin, T. Maruyama, M. J. Nolan, P. M. Calveley, J. D. Malone, M. R. Wallace, and K. S. Bowdish. 2003. Human antibodies from immunized donors are protective against anthrax toxin in vivo. Nat. Biotechnol. 21:1305-1306.
57. Wimer-Mackin, S., M. Hinchcliffe, C. R. Petrie, S. J. Warwood, W. T. Tino, M. S. Williams, J. P. Stenz, A. Cheff, and C. Richardson. 2006. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits. Vaccine 24:3953-3963.
58. Xu, W., B. A. Smith-Franklin, P. L. Li, C. Wood, J. He, Q. Du, G. J. Bhat, C. Kankasa, H. Katinger, L. A. Cavacini, M. R. Posner, D. R. Burton, T. C. Chou, and R. M. Ruprecht. 2001. Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B. J. Hum. Virol. 4:55-61.
59. Zhao, P., X. Liang, J. Kalbfleisch, H. M. Koo, and B. Cao. 2003. Neutralizing monoclonal antibody against anthrax lethal factor inhibits intoxication in a mouse model. Hum. Antibodies 12:129-135.
60. Ziegler-Heitbrock, H. W., C. Reiter, J. Trenkmann, A. Futterer, and G. Riethmuller. 1986. Protection of mice against tetanus toxin by combination of two human monoclonal antibodies recognizing distinct epitopes on the toxin molecule. Hybridoma 5:21-31.